Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trialAna Oaknin, Juan Cueva, Laurence Gladieff et al.|The Lancet|2023Cited by 225
LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum lineNicoletta Colombo, Andrés Poveda, G-B. Nyvang et al.|Annals of Oncology|2020Cited by 23